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Abstract:  As a first line of defence against a virus infection, mammalian cells elicit an innate immune response, 
characterized by secretion of type I interferons (IFN) and up-regulation of interferon stimulated genes (ISGs). We have 
previously included Crimean Congo Hemorrhagic Fever Virus (CCHFV) in the list of type I IFN-sensitive viruses. In this 
in vitro study, we have compared the antiviral activity of two recombinant IFN-alpha preparations (Roferon A and Intron 
A) with a natural IFN-alpha produced in human leukocytes (Multiferon). Our results clearly demonstrate that these 
commercially available IFNs have significant antiviral activities against CCHFV. However, we could show that 
Multiferon inhibits viral replication more efficiently than the two recombinant IFN alpha preparations. 
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INTRODUCTION 
  The innate immune response represents the first line of 
defence against a viral infection in mammalian cells [1, 2]. 
The immune system is triggered when molecules produced 
during viral replication are detected by receptors on the 
surface or inside the host cell. Upon sensing those 
molecules, signalling pathways are activated leading to 
induction and secretion of type I interferons (IFNs), both 
IFN-alpha and IFN-beta, and subsequent up-regulation of 
interferon stimulated genes (ISGs) [3]. Type I IFNs are 
important mediators of innate immune
  responses and are 
crucial for limiting early replication and
  spread of viruses 
[3]. They induce a number of proteins involved
 in antiviral 
actions, such as 2',5'-oligoadenylate synthetase [4, 5],
 
double-stranded RNA-activated protein kinase (PKR) [6], or 
Mx
 proteins [7-9]. In turn, the ISGs mediate antiviral, anti-
proliferative and immunomodulatory effects to protect 
surrounding cells from viral infections. 
  The importance of the IFN system is illustrated by the fact 
that numerous viruses encode gene products with antagonistic 
properties against the IFN-induced antiviral response [10]. 
 The  Bunyaviridae family is the largest virus family 
consisting of more than 300 enveloped viruses containing an 
RNA genome in negative-sense orientation [11]. The 
genome is divided into three segments designated L, M and 
S encoding an RNA-dependent RNA polymerase, two 
glycoproteins (Gc and Gn) and a nucleocapsid protein (NP), 
respectively [12]. In addition, some members of the family 
encode non-structural proteins on their M or S segment 
termed NSm or NSs, respectively [13, 14]. Despite the 
increasing knowledge of the biology of the Bunyaviridae  
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family, little is known about Crimean Congo Hemorrhagic 
Fever Virus (CCHFV), a virus classified within the 
Nairovirus genus in this family and the causative agent of a 
severe hemorrhagic fever in humans [15]. The virus is 
transmitted either through bites by infected Ixodid ticks, or 
by direct contact with virus-contaminated blood. Even the 
nosocomial transmission has been reported. 
  The mortality rate varies depending on the mode of 
transmission; the reported mortality is 10–50% in cases of 
tick-to-human transmission, but even higher in the case of 
nosocomial infections [12, 16, 17]. Crimean Congo 
Hemorrhagic Fever (CCHF) progression is rapid. In severe 
cases, there is a short incubation period of 1 to 3 days after a 
tick bite before, severe hemorrhagic manifestations develop 
on the third to fifth day of disease, with death occurring 
during the second week of illness [15]. 
  We have previously shown that type I IFNs have an 
antiviral effect against CCHFV [18], most likely due to the 
activities of IFN-induced antiviral proteins such as MxA [7], 
PKR or ISG20 (manuscripts in preparation). In this study, 
we have compared the in vitro antiviral activity of different 
recombinant IFNs and naturally produced IFN from human 
leukocytes. 
  Roferon A [19, 20] and Intron A [21] are recombinant forms 
of IFN subtypes alpha-2a and -2b, respectively. These proteins 
have been manufactured by recombinant DNA technology. 
Multiferon [22, 23] is a natural IFN-alpha, which is obtained 
from the leukocyte fraction of human blood following induction 
with Sendai virus and subsequently purified by affinity 
chromatography. Multiferon contains various physiologically 
active IFN-alpha subtypes. 
COMMERCIALLY AVAILABLE MULTIFERON HAS 
A BETTER ANTIVIRAL ACTIVITY COMPARED TO 
INTRON A AND ROFERON A 
  In order to compare the antiviral activity of the 
commercially available IFNs, A549 cells were treated with Comparison of Antiviral Activity of Recombinant and Natural Interferons  The Open Virology Journal, 2010, Volume 4    39 
different concentrations (10, 100 and 1000 IU/ml) of 
Multiferon, Roferon A or Intron A. Twenty four hours after 
treatment cells were infected with CCHFV strain IbAr 
10200, originally isolated in Nigeria in 1970, at various 
multiplicities of infection (MOI) ranging from 0.1 to 1 [24, 
25]. Supernatants and cell lysates from mock- or IFN-treated 
cells were collected for detection of viral RNA and/or viral 
proteins at 48 hours post infection (h.p.i.). 
  Viral RNA was purified using the QIAamp Viral RNA 
Mini Kit (Qiagen) according to the manufacturer’s 
instructions. Real-time reverse transcription-PCRs were 
performed as previously described by Wölfel et al. [26]. 
Briefly, primers targeting a 181 bp-long region in the S 
segment combined with 3 probes were included in the assay. 
Five microliters of extracted RNA were then used as a 
template in a 25 l reaction volume and the cycling reactions 
were performed in a Roche Light Cycler 2.0. Reactions with 
crossing points below 35 cycles were defined as positive and 
plotted against a standard curve. Genome contents were 
calculated and presented as genomes/ml. 
  As shown in Fig. (1a), we could clearly demonstrate that 
Roferon A, Intron A and Multiferon have significant 
antiviral activities against CCHFV. These data could show 
that treatment of cells with 100 IU/ml of either Roferon A or 
Intron A inhibits the replication of CCHFV by at least one 
log while treatment with Multiferon inhibits viral replication 
by even two logs. Thus, Multiferon has a 10-times higher 
antiviral activity against CCHFV as compared to the 
(a) 
 
(b) 
Fig. (1). a) Multiferon inhibits more efficiently the replication cycle of CCHFV compared to the others commercially available interferons. 
A549 cells were treated with different concentrations of IFNs for 24h. Mock-treated and IFN-treated cells were then infected with CCHFV 
(MOI 1). After another 48h cell supernatants were collected and analyzed by real-time RT-PCR. Error bars demonstrate ± SD based on three 
separate experiments. b) Comparison of inhibition of CCHFV genome contents in cell supernatants after pre-treated with different 
concentrations of Multiferon. A549 cells were treated with different concentrations of Multiferon for 24h. The mock-treated and Multiferon-
treated cells were then infected with CCHFV (MOI 0,1 and 1). After another 48h cell supernatants were collected and analyzed by real-time 
RT-PCR. 
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recombinant IFNs. As expected, the antiviral activity of 
Multiferon was even more pronounced when the pre-treated 
cells were infected with less virus (Fig. 1b). 
  To confirm these results, we analyzed the expression of 
CCHFV NP in mock-treated and IFN-treated cells by 
Western blot (WB) (Fig. 2). 
Fig. (2). Cells were pre-treated with either Roferon A (R), Intron A 
(I) or Multiferon (M) at different concentrations for 24h. Cells were 
then infected with CCHFV (MOI 0,1-1) and 24h later cell lysates 
were harvested for Western Blot analysis. 
  Cell lysates were resuspended in reducing sample buffer, 
boiled for five minutes and separated on SDS-PAGE with a 
5%-concentration gel and 10%-separation gel. Electrophore-
sis was carried out at a constant current of 25 A. Proteins 
were transferred to a nitrocellulose membrane at 100 V for 
1h using a transfer buffer containing 25 mM Tris, 192 mM 
glycine and 20% (v/v) methanol. Membranes were then 
blocked in 5% non-fat dry milk over night at +4˚C. After 
washing in PBS containing 0.01% Tween (PBST), the 
membranes were incubated with a polyclonal rabbit-anti-
CCHFV NP-antibody in dilution buffer (5% non-fat dry milk 
in PBST) for 1h at room temperature. The membranes were 
then washed three times with PBST before incubating them 
with goat-anti-rabbit IgG HRP-conjugated antibody in 
dilution buffer for 1h at room temperature. After careful 
washing, detection was carried out using ECL Plus Western 
Blotting Detection Reagents (Amersham Pharmacia) 
according to the manufacturer’s instructions. 
  As shown in Fig. (2), Roferon A, Intron A and Multi-
feron reduced the expression of NP significantly. Moreover, 
these results confirm that Multiferon has a higher antiviral 
activity against CCHFV as compared to the other IFNs. 
  In this study, we demonstrate that commercially available 
IFN-alpha preparations have a strong antiviral activity 
against CCHFV when the cells are pre-treated before 
infection. We could also show that the naturally produced 
IFN from human leukocytes, Multiferon, has a significantly 
higher antiviral activity in vitro compared to recombinant 
IFNs. This study did not address the specific reason for the 
observed superior efficiency of Multiferon. However, 
Multiferon contains several naturally occurring subtypes of 
IFN-alpha and could therefore activate the antiviral state of 
the treated cells more efficiently. 
  IFNs are key players in host responses in the very early 
steps of infection [10, 27]. The use of IFNs as therapeutics 
began soon after their potent antiviral activity had been 
discovered [28, 29]. Today, recombinant IFN-alpha is 
established as a key component of Hepatitis C treatment 
strategies, widely used in patients with chronic disease [30]. 
In recent years, it has been demonstrated that the use of IFN-
alpha in combination with ribavirin [31] yielded much higher 
success rates of the treatment. Moreover, it has been shown 
that switching to purified IFN-alpha from human leukocytes 
during an antiviral treatment could achieve a sustained 
immune response in patients [22, 23]. Clinical studies have 
demonstrated that IFN has antiviral activity also against 
rhinovirus [32]. A recent study by Kugel et al. suggests that 
IFN treatment by nasal route may protect high risk groups 
against seasonal influenza [33]. 
  The only known and used antiviral drug against CCHFV 
is ribavirin, a synthetic guanosine analogue [12]. Ribavirin 
has been approved for clinical use during treatment of, 
amongst other, Hepatitis C virus or respiratory syncytial 
virus infections [34-36] and is used off-label for treatment of 
patients with CCHFV infections [37-40]. However, the 
mechanism of action of ribavirin against CCHFV is still 
poorly understood and a discussion is still ongoing whether 
or not patients infected with CCHFV actually benefit from 
being treated with this drug. Whether IFN-alpha can be 
beneficial for treatment of patients with CCHFV in very 
early phase of disease alone or combination with ribavirin is 
not addressed before. It should be mentioned that interferon 
most probably induce the inflammatory response in these 
patients, and thereby can have a negative effect in progress 
of the disease. However, to address if IFN-alpha can be used 
as treatment in very early step of infection or as prophylaxis 
for persons exposed to the virus, detailed studies in animal 
models are needed. 
ACKNOWLEDGEMENT 
  This study has partly been supported by Swedish Orphan 
International. 
REFERENCES 
[1]  Bonjardim CA, Ferreira PC, Kroon EG. Interferons: signaling, 
antiviral and viral evasion. Immunol Lett 2009; 122: 1-11. 
[2]  Garcia-Sastre A, Biron CA. Type 1 interferons and the virus-host 
relationship: a lesson in detente. Science 2006; 312: 879-82. 
[3]  Randall RE, Goodbourn S. Interferons and viruses: an interplay 
between induction, signalling, antiviral responses and virus 
countermeasures. J Gen Virol 2008; 89: 1-47. 
[4]  Silverman RH. Viral encounters with 2',5'-oligoadenylate 
synthetase and RNase L during the interferon antiviral response. J 
Virol 2007; 81: 12720-9. 
[5]  Silverman RH. A scientific journey through the 2-5A/RNase L 
system. Cytokine Growth Factor Rev 2007; 18: 381-8. 
[6]  Samuel MA, Whitby K, Keller BC, et al. PKR and RNase L 
contribute to protection against lethal West Nile Virus infection by 
controlling early viral spread in the periphery and replication in 
neurons. J Virol 2006; 80: 7009-19. 
[7]  Andersson I, Bladh L, Mousavi-Jazi M, et al. Human MxA protein 
inhibits the replication of Crimean-Congo hemorrhagic fever virus. 
J Virol 2004; 78: 4323-9. 
[8]  Brzozka K, Finke S, Conzelmann KK. Identification of the rabies 
virus alpha/beta interferon antagonist: phosphoprotein P interferes 
with phosphorylation of interferon regulatory factor 3. J Virol 
2005; 79: 7673-81. 
[9]  Haller O, Frese M, Kochs G. Mx proteins: mediators of innate 
resistance to RNA viruses. Rev Sci Tech 1998; 17: 220-30. 
[10]  Haller O, Weber F. The interferon response circuit in antiviral host 
defense. Verh K Acad Geneeskd Belg 2009; 71: 73-86. 
[11]  Schmaljohn A, Hooper JW. Bunyaviridae: the viruses and their 
replication. In: Knipe DM, Howley PM, Eds. Fields Virology, 
Lippincott, Williams and Wilkins: Philadelpia 2001; pp. 1447-72. Comparison of Antiviral Activity of Recombinant and Natural Interferons  The Open Virology Journal, 2010, Volume 4    41 
[12]  Whitehouse, C.A. Crimean-Congo hemorrhagic fever. Antiviral 
Res 2004; 64: 145-60. 
[13]  Erickson BR, Deyde V, Sanchez AJ, Vincent MJ, Nichol ST. N-
linked glycosylation of Gn (but not Gc) is important for Crimean 
Congo hemorrhagic fever virus glycoprotein localization and 
transport. Virology 2007; 361: 348-55. 
[14]  Ikegami T, Won S, Peters CJ, Makino S. Rift Valley fever virus 
NSs mRNA is transcribed from an incoming anti-viral-sense S 
RNA segment. J Virol 2005; 79: 12106-11. 
[15]  Weber F, Mirazimi A. Interferon and cytokine responses to 
Crimean Congo hemorrhagic fever virus; an emerging and 
neglected viral zonoosis. Cytokine Growth Factor Rev 2008; 19: 
395-404. 
[16]  Swanepoel R. Crimean-Congo haemorrhagic fever. Cape Town: 
Oxford University Press 1994; pp. 723-9. 
[17]  Swanepoel R, Shepherd AJ, Leman PA, et al. Epidemiologic and 
clinical features of Crimean-Congo hemorrhagic fever in southern 
Africa. Am J Trop Med Hyg 1987; 36: 120-32. 
[18]  Andersson I, Lundkvist A, Haller O, Mirazimi A. Type I interferon 
inhibits Crimean-Congo hemorrhagic fever virus in human target 
cells. J Med Virol 2006; 78: 216-22. 
[19]  Brook MG, McDonald JA, Karayiannis P, et al. Randomised 
controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the 
treatment of chronic hepatitis B virus (HBV) infection: factors that 
influence response. Gut 1989; 30: 1116-22. 
[20]  Lai CL, Lok AS, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Placebo-
controlled trial of recombinant alpha 2-interferon in Chinese 
HBsAg-carrier children. Lancet 1987; 2: 877-80. 
[21]  Choueiri TK, Hutson TE, Bukowski RM. Evolving role of 
pegylated interferons in metastatic renal cell carcinoma. Expert 
Rev Anticancer Ther 2003; 3: 823-9. 
[22]  Musch E, Malek M, von Eick H, Chrissafidou A. Successful 
application of highly purified natural interferon alpha (multiferon) 
in a chronic hepatitis C patient resistant to preceding treatment 
approaches. Hepatogastroenterology 2004; 51: 1476-9. 
[23]  Musch E, Malek M, von Eick H, Chrissafidou A. Successful long-
term application of highly purified natural interferon-alpha 
(multiferon) after preceding interferon approaches in a chronic 
hepatitis C patient with thrombocytopenia. Scand J Infect Dis 2004; 
36: 395-9. 
[24]  Andersson I, Simon M, Lundkvist A, et al. Role of actin filaments 
in targeting of Crimean Congo hemorrhagic fever virus 
nucleocapsid protein to perinuclear regions of mammalian cells. J 
Med Virol 2004; 72: 83-93. 
[25]  Flick R, Flick K, Feldmann H, Elgh F. Reverse genetics for 
crimean-congo hemorrhagic fever virus. J Virol 2003; 77: 5997-
6006. 
[26]  Wölfel R, Paweska JT, Petersen N, et al. Virus detection and 
monitoring of viral load in Crimean-Congo hemorrhagic fever virus 
patients. Emerg Infect Dis 2007; 13: 1097-100. 
[27]  Weber F, Haller O. Viral suppression of the interferon system. 
Biochimie 2007; 89: 836-42. 
[28]  Borecky L. Current view on the perspectives of interferon therapy. 
Acta Virol 1986; 30: 161-9. 
[29]  Borecky L, Fuchsberger N. Interferon as therapeutic agent. Acta 
Virol 1983; 27: 359-70. 
[30]  Hoofnagle JH, Seeff B. Peginterferon and ribavirin for chronic 
hepatitis C. N Engl J Med 2006; 355: 2444-51. 
[31]  McHutchison J, Blatt L, Sedghi-Vaziri A, Russell J, Schmid P, 
Conrad A. Is there an optimal time to measure quantitative HCV 
RNA to predict non-response following interferon treatment for 
chronic HCV infection? J Hepatol 1998; 29: 362-8. 
[32]  Finter NB, Chapman S, Dowd P, et al. The use of interferon-alpha 
in virus infections. Drugs 1991; 42: 749-65. 
[33]  Kugel D, Kochs G, Obojes K, et al. Intranasal administration of 
alpha interferon reduces seasonal influenza A virus morbidity in 
ferrets. J Virol 2009; 83: 3843-51. 
[34]  Wawrzynowicz-Syczewska M. Ribavirin--pharmacological features, 
antiviral effects against hepatitis C virus (HCV) and other viruses 
and side effects during treatment. Przegl Epidemiol 2002; 56(Suppl 
5): 35-40. 
[35]  Schleuning M, Buxbaum-Conradi H, Jäger G, Kolb HJ. 
Intravenous ribavirin for eradication of respiratory syncytial virus 
(RSV) and adenovirus isolates from the respiratory and/or 
gastrointestinal tract in recipients of allogeneic hematopoietic stem 
cell transplants. Hematol J 2004; 5: 135-44. 
[36]  Cooper KE. The effectiveness of ribavirin in the treatment of RSV. 
Pediatr Nurs 2001; 27: 95-8. 
[37]  Ergonul O, DEBATE (see Elaldi N, et al. Efficacy of oral ribavirin 
treatment in Crimean-Congo haemorrhagic fever: a quasi-
experimental study from Turkey. Journal of Infection 2009; 58: 
238-244): biases and misinterpretation in the assessment of the 
efficacy of oral ribavirin in the treatment of Crimean-Congo 
hemorrhagic fever. J Infect 2009; 59: 284-6. 
[38]  Dizbay M, Aktas F, Gaygisiz U, Ozger HS, Ozdemir K. Crimean-
Congo hemorrhagic fever treated with ribavirin in a pregnant 
woman. J Infect 2009; 59: 281-3. 
[39]  Tasdelen Fisgin N, Ergonul O, Doganci L, Tulek N. The role of 
ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early 
use is promising. Eur J Clin Microbiol Infect Dis 2009; 28: 929-33. 
[40]  Izadi S, Salehi M. Evaluation of the efficacy of ribavirin therapy on 
survival of Crimean-Congo hemorrhagic fever patients: a case-
control study. Jpn J Infect Dis 2009; 62: 11-5. 
 
 
Received: November 9, 2009  Revised: December 2, 2009  Accepted: December 3, 2009 
 
© Karlberg et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http: //creativecommons.org/licenses/by-nc/ 
3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
 